Eculizumab in Pediatric and Adult Participants with Atypical Hemolytic Uremic Syndrome (aHUS) in China

Trial Identifier: D7413C00001
Sponsor: Alexion Pharmaceuticals, Inc.
Collaborator:
Astrazeneca
NCTID:: NCT05876351
Start Date: July 2023
Primary Completion Date: March 2026
Study Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100034
CN Beijing, CN, 100045
CN Changsha, CN, 410007
CN Chengdu, CN, 610041
CN guangzhou, CN, 510062
CN Nanchang, CN, 330006
CN nanjing, CN, 210002
CN Qingdao, CN, 110016
CN Shenzhen, CN, 518036
CN Suzhou, CN, 215002
CN Taiyuan, CN, 030012
CN Wuhan, CN, 430030
CN Yantai, CN, 264000
CN Zhengzhou, CN, 450018
CN Zhengzhou, CN, 450052